WISE Indiana
Expert Directory Form

Regenstrief Institute COVID-19 Dashboard

IUSM Library COVID-19
Research Guide

IUPUI COVID-19
ECHO Registration

Johns Hopkins COVID-19
POC Guide

NCBI LitCovid
Literature Hub

wisein@iu.edu | 317-274-7155

INDIANA TO BEGIN OFFERING PFIZER COVID-19 BOOSTER SHOTS FOR ELIGIBLE HOOSIERS FOLLOWING FDA, CDC ACTIONS (IDOH)
The Indiana Department of Health announced on Friday, September 24th, that booster doses of Pfizer’s COVID-19 vaccine are available to eligible Hoosiers following federal authorization of the additional dose.

Eligible Hoosiers who want to obtain a booster dose can go to www.ourshot.in.gov and search for a site that has the Pfizer vaccine, which is designated by PVAX, or call 211 for assistance. Hoosiers are encouraged to bring their vaccination card to their appointment to ensure that the booster dose is added.

2021 Reciprocal Innovation Stakeholder Meeting (CTSI)
The 2021 Reciprocal Innovation (RI) Stakeholder’s Meeting will be held virtually on Wednesday, October 13. Dr. Roger Glass, director of the Fogarty International Center and associate director for International Research at the National Institutes of Health, will be this year’s keynote speaker. Event discussion will focus on the concept of reciprocal innovation and knowledge we’ve gained during the COVID-19 pandemic to strengthen health systems. Registration is now open.

IHIE Indiana COVID-19 Vaccination Data Report (IHIE)
The intent of these documents is to provide weekly updates on county-specific vaccination rates, particularly as they compare to hesitant or vulnerable populations, to help identify where vaccination outreach opportunities and planning efforts should be focused.

Indiana COVID-19 Vaccination Dashboard (IDOH)
IDOH’s Vaccination Dashboard provides updates on Indiana’s progress to vaccinate Hoosiers against COVID-19. Data is updated at 12:00 PM EST.

IDOH COVID-19 Page
Indiana FSSA COVID-19 Page

FDA Authorizes Booster Dose of Pfizer-BioNTech COVID-19 Vaccine for Certain Populations (FDA)
the U.S. Food and Drug Administration amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine to allow for use of a single booster dose, to be administered at least six months after completion of the primary series in individuals 65 years of age and older, individuals 18 through 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age whose frequent institutional or occupational exposure to SARS-CoV-2 puts them at high risk of serious complications of COVID-19 including severe COVID-19.

World Health Organization Weekly Epidemiological Update (WHO)
The numbers of weekly COVID-19 cases and deaths globally continued to decline this week, with over 3.6 million cases and just under 60,000 deaths reported between 13-19 September. This brings the cumulative number of confirmed cases reported globally to just under 228 million. While the African and the European Regions reported numbers of cases similar to those of the previous week, the other regions reported decreases in weekly case incidence, with substantial decreases reported in the Eastern Mediterranean (22%) and South East Asia Regions (16%).

In terms of COVID-19 mortality, nearly 60,000 deaths were reported globally in the past week, a 7% decrease as compared to the previous week. This brings the cumulative number of deaths to over 4.6 million. The African, Eastern Mediterranean and South-East Asian Regions reported decreases in weekly mortality over the past week, with the South-East Asia Region reporting the largest percentage decrease (27%). In contrast, the Western Pacific Region reported an increase (7%) in the number of new weekly deaths, while the number of deaths reported in Americas and European Regions reported was similar to that of the previous week.

WHO COVID-19 Page
CDC COVID-19 Page

These documents were prepared by teams of research librarians and faculty experts in response to specific questions posed by individuals involved in Indiana’s frontline COVID-19 response. They summarize information that frontline responders may find useful. Please note that information is current for the dates specified. New studies, priorities and literature are being published daily, and best practices are rapidly evolving. These documents do not represent clinical guidelines, standard operating procedures, or the opinions or positions of FSSA.

• Is there evidence that vaccine incentives work to increase COVID-19 vaccination rates (especially among vulnerable populations), and if so – which incentives work best?
• Who is most at risk for COVID-19 Delta variant infection even if fully vaccinated?
• Vaccination Recommendations for Pregnant Individuals
• Pfizer Summary of Vaccine Characteristics and Progress
• Moderna Summary of Vaccine Characteristics and Progress
• Johnson & Johnson Summary of Vaccine Characteristics and Progress